Orexo AB’s Abstral(TM) Receives Two Further Large EU Market Approvals in France and Spain

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX), announces that AbstralTM has received Marketing Authorisation from the French and Spanish regulatory authorities for the treatment of breakthrough cancer pain.
MORE ON THIS TOPIC